RedHill Biopharma (RDHL) Financial Statements

Compare

875 Followers

RedHill Biopharma Financial Overview

RedHill Biopharma's market cap is currently $3.98M. The company's EPS TTM is $; its P/E ratio is -0.42; RedHill Biopharma is scheduled to report earnings on March 12, 2026, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 24	Dec 23	Mar 23	Dec 21	Dec 20
Income Statement
Total Revenue	$ 8.04M	$ 6.53M	$ 61.80M	$ 85.76M	$ 64.36M
Gross Profit	$ 4.85M	$ 3.07M	$ 28.46M	$ 36.35M	$ 27.47M
Operating Income	$ -14.61M	$ 12.63M	$ -42.84M	$ -81.14M	$ -63.68M
EBITDA	$ -7.59M	$ 26.27M	$ -22.18M	$ -63.03M	$ -54.98M
Net Income	$ -8.27M	$ 23.92M	$ -71.67M	$ -97.74M	$ -76.17M
Balance Sheet
Cash & Short-Term Investments	$ 4.62M	$ 6.36M	$ 19.98M	$ 38.00M	$ 29.79M
Total Assets	$ 18.04M	$ 23.05M	$ 158.87M	$ 181.19M	$ 180.24M
Total Debt	$ 356.00K	$ 1.17M	$ 122.69M	$ 87.81M	$ 86.90M
Net Debt	$ -4.26M	$ -4.40M	$ 102.72M	$ 58.34M	$ 57.61M
Total Liabilities	$ 22.73M	$ 20.98M	$ 207.27M	$ 172.31M	$ 166.38M
Stockholders' Equity	$ -4.68M	$ 2.07M	$ -48.40M	$ 8.88M	$ 13.86M
Cash Flow
Free Cash Flow	$ -9.38M	$ -35.83M	$ -29.38M	$ -65.16M	$ -102.35M
Operating Cash Flow	$ -9.37M	$ -35.82M	$ -29.18M	$ -65.05M	$ -48.58M
Investing Cash Flow	$ -9.00K	$ 3.99K	$ 8.30M	$ -8.14M	$ -35.65M
Financing Cash Flow	$ 8.42M	$ 21.38M	$ 11.45M	$ 73.46M	$ 84.37M

Currency in USD

RedHill Biopharma Earnings and Revenue History

Income Statement >

RedHill Biopharma Debt to Assets

Balance Sheet >

RedHill Biopharma Cash Flow

Cash Flow >

RedHill Biopharma Forecast EPS vs Actual EPS

Currently, no data available

Please return soon. This page is being updated.

Earnings >